Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Archive Search

8 results
12:00 AM, Feb 17, 2014  |  BC Week In Review | Clinical News  |  Clinical Results

AVI-7288: Phase I data

healthy volunteers showed that once-daily 1, 4, 8, 12 and 16 mg/kg doses of IV AVI-7288
or clinically significant adverse events reported. Sarepta is developing the IV and intramuscular formulations of AVI-7288
was awarded in July 2010 and the intramuscular formulation contract was awarded in August 2012. AVI-7288
12:00 AM, May 13, 2013  |  BC Week In Review | Clinical News  |  Clinical Status

AVI-7288: Phase I started

Phase I trial to evaluate multiple ascending-doses of 1, 3, 6 and 9 mg/kg IV AVI-7288
14 days in 32 healthy volunteers. Sarepta is developing the IV and intramuscular formulations of AVI-7288
was awarded in July 2010, and the intramuscular formulation contract was awarded in August 2012. AVI-7288
12:00 AM, Mar 11, 2013  |  BC Week In Review | Clinical News  |  Preclinical Results

Sarepta Therapeutics preclinical data

In non-human primates infected with Marburg virus, once-daily 7.5-30 mg/kg doses of intramuscular AVI-7288 given 1 …
over a 40-day evaluation period vs. 0% for placebo. Last year, Sarepta reported that IV AVI-7288
2012). Also last year, Sarepta completed a Phase I trial evaluating single ascending-doses of IV AVI-7288
12:00 AM, Sep 24, 2012  |  BC Week In Review | Clinical News  |  Regulatory

AVI-7288 regulatory update

FDA granted Fast Track designation for Sarepta's AVI-7288 to treat Marburg virus infection and AVI-7537 to …
in humans. Next quarter, Sarepta plans to begin a multiple ascending-dose Phase I trial with AVI-7288
see BioCentury, Aug. 13 & Sept. 10). Sarepta Therapeutics Inc. (NASDAQ:SRPT), Bothell, Wash.   Product: AVI-7288
12:00 AM, Sep 24, 2012  |  BC Week In Review | Clinical News  |  Regulatory

AVI-7537 regulatory update

FDA granted Fast Track designation for Sarepta's AVI-7288 to treat Marburg virus infection and AVI-7537 to …
in humans. Next quarter, Sarepta plans to begin a multiple ascending-dose Phase I trial with AVI-7288
12:00 AM, Jul 30, 2012  |  BC Week In Review | Clinical News  |  Preclinical Results

Sarepta Therapeutics preclinical data

In non-human primates infected with Marburg virus, AVI-7288 given 1, 24, 48 or 96 hours post-infection …
oligomers (PMO) antisense chemistry is in Phase I testing for the indication. Sarepta is developing AVI-7288
a July 2010 contract from the U.S. Department of Defense's Transformational Medical Technologies (TMT) program. AVI-7288
12:00 AM, Apr 09, 2012  |  BC Week In Review | Clinical News  |  Clinical Results

AVI-6003: Phase I data

Instead, the company plans to begin a Phase I trial to evaluate multiple ascending-doses of AVI-7288
but did not disclose a time frame (see BioCentury, March 5). AVI BioPharma is developing AVI-7288
Transformational Medical Technologies (TMT) program, which was originally supporting AVI-6003 (see BioCentury, July 19, 2010). AVI-7288
12:00 AM, Mar 05, 2012  |  BC Week In Review | Clinical News  |  Clinical Status

AVI-7288: Phase I start

BioPharma said it received approval from FDA to begin preclinical and Phase I testing of AVI-7288
BioPharma plans to begin a double-blind, placebo-controlled Phase I trial to evaluate multiple ascending-doses of AVI-7288
volunteers. The company did not disclose a timeline for the start. AVI BioPharma is developing AVI-7288